## expected % of district-level cases in trial population CoxME, 2.5% CoxME, 5% CoxME, 7.5% CoxME, 10% 1 1 -1 0.5 0.5 0.5 0.5 0.25 0.25 0.25 0.25 0.1 0.1 0.1 0.1 0.05 0.05 0.05 0.05 0.025 0.025 0.025 0.025 proportion rejecting null hypothesis that vaccine does not affect risk 0.01 0.01 0.01 0.01 0.50.70.9 0.50.70.9 0.50.70.9 0.50.70.9 0 0 0 0 GLMFclus, 2.5% GLMFclus, 5% GLMFclus, 7.5% GLMFclus, 10% 0.5 0.5 0.5 0.5 0.25 0.25 0.25 0.25 0.1 0.1 0.1 0.1 analysis 0.05 0.05 0.05 0.05 0.025 0.025 0.025 0.025 (A) SWCT including early/late person-time 0.01 0.01 0.01 0.01 & excluding protective delay 0.50.70.9 0.50.70.9 0.50.70.9 0.50.70.9 0 0 0 (B) SWCT excluding both protective delay bootCoxME, 2.5% bootCoxME, 5% bootCoxME, 7.5% bootCoxME, 10% & early/late person-time 0.5 0.5 0.5 -0.5 (C) SWCT including protective delay 0.25 0.25 0.25 0.25 & early/late person-time 0.1 0.1 0.1 0.1 0.05 0.05 0.05 0.05 0.025 0.025 0.025 0.025 0.01 0.01 0.01 · 0.01 0 0.50.70.9 0 0.50.70.9 0 0.50.70.9 0 0.50.70.9 relabCoxME, 2.5% relabCoxME, 5% relabCoxME, 7.5% relabCoxME, 10% 1 0.5 0.5 0.5 0.5 0.25 0.25 0.25 0.25 0.1 0.1 0.1 0.1 0.05 0.05 0.05 0.05 0.025 0.025 0.025 0.025 0.01 0.01 0.01 0.01

0.50.70.9

0.50.70.9

0.50.70.9

vaccine efficacy

0

0

0.50.70.9